172 related articles for article (PubMed ID: 38751641)
1. Insights into Mechanisms and Promising Triple Negative Breast Cancer Therapeutic Potential for a Water-Soluble Ruthenium Compound.
Nayeem N; Sauma S; Ahad A; Rameau R; Kebadze S; Bazett M; Park BJ; Casaccia P; Prabha S; Hubbard K; Contel M
ACS Pharmacol Transl Sci; 2024 May; 7(5):1364-1376. PubMed ID: 38751641
[TBL] [Abstract][Full Text] [Related]
2. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the Effects and Mechanisms of Anticancer Action of a Ru(II)-Arene Iminophosphorane Compound in Triple Negative Breast Cancer Cells.
Nayeem N; Yeasmin A; Cobos SN; Younes A; Hubbard K; Contel M
ChemMedChem; 2021 Nov; 16(21):3280-3292. PubMed ID: 34329530
[TBL] [Abstract][Full Text] [Related]
4. Intracellular Localization Studies of the Luminescent Analogue of an Anticancer Ruthenium Iminophosphorane with High Efficacy in a Triple-Negative Breast Cancer Mouse Model.
Miachin K; Del Solar V; El Khoury E; Nayeem N; Khrystenko A; Appelt P; Neary MC; Buccella D; Contel M
Inorg Chem; 2021 Dec; 60(24):19152-19164. PubMed ID: 34846878
[TBL] [Abstract][Full Text] [Related]
5. The trans-[Ru(PPh
Becceneri AB; Popolin CP; Plutin AM; Maistro EL; Castellano EE; Batista AA; Cominetti MR
J Inorg Biochem; 2018 Sep; 186():70-84. PubMed ID: 29857173
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
7. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
[TBL] [Abstract][Full Text] [Related]
8. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
9. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.
Bilir B; Kucuk O; Moreno CS
J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694
[TBL] [Abstract][Full Text] [Related]
10. Transport of the Ruthenium Complex [Ru(GA)(dppe)
Naves MA; Graminha AE; Vegas LC; Luna-Dulcey L; Honorato J; Menezes ACS; Batista AA; Cominetti MR
Mol Pharm; 2019 Mar; 16(3):1167-1183. PubMed ID: 30633527
[TBL] [Abstract][Full Text] [Related]
11. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
12. Elevated estrogen receptor β expression in triple negative breast cancer cells is associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway.
Lei S; Fan P; Wang M; Zhang C; Jiang Y; Huang S; Fang M; He Z; Wu A
Exp Ther Med; 2020 Aug; 20(2):1630-1636. PubMed ID: 32742395
[TBL] [Abstract][Full Text] [Related]
13. The Anticancer Effects of Marine Carotenoid Fucoxanthin through Phosphatidylinositol 3-Kinase (PI3K)-AKT Signaling on Triple-Negative Breast Cancer Cells.
Ahmed SA; Mendonca P; Messeha SS; Oriaku ET; Soliman KFA
Molecules; 2023 Dec; 29(1):. PubMed ID: 38202644
[TBL] [Abstract][Full Text] [Related]
14. Radix Tetrastigma Extracts Enhance the Chemosensitivity in Triple-Negative Breast Cancer Via Inhibiting PI3K/Akt/mTOR-Mediated Autophagy.
Zhang S; Cui T; Duan Y; Zhang H; Wang B; Chen H; Ni J; Shen Y; Xiao-Ai Lv
Clin Breast Cancer; 2022 Feb; 22(2):89-97. PubMed ID: 34535390
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway.
Hu H; Zhu J; Zhong Y; Geng R; Ji Y; Guan Q; Hong C; Wei Y; Min N; Qi A; Zhang Y; Li X
Ann Transl Med; 2021 Mar; 9(5):410. PubMed ID: 33842631
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR
PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.
Tarasewicz E; Rivas L; Hamdan R; Dokic D; Parimi V; Bernabe BP; Thomas A; Shea LD; Jeruss JS
Cell Cycle; 2014; 13(20):3191-201. PubMed ID: 25485498
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967
[TBL] [Abstract][Full Text] [Related]
20. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]